Information Provided By:
Fly News Breaks for September 9, 2019
ARDX
Sep 9, 2019 | 05:13 EDT
Piper Jaffray analyst Christopher Raymond says he still expects "substantial upside" in shares of Ardelyx even after last week's 43% move. While Amplify's more "real world" representation assuaged the key investor concern around tenapanor's adverse event-related discontinuations, the market still hasn't grasped tenapanor's full market potential in the renal setting, Raymond tells investors in a research note. Feedback from a recent nephrologist survey indicates "significant" awareness, interest and willingness to prescribe tenapanor, adds the analyst. He sees the drug's revenue potential "at well" over $1B in the U.S. alone. As such, Raymond continues to view his $15 target as a "more appropriate valuation" than current share levels. He maintains an Overweight rating on Ardelyx.
News For ARDX From the Last 2 Days
There are no results for your query ARDX